Treatment regimens for multiple myeloma have expanded significantly over the last decade and have improved outcomes in patients. This expansion has created knowledge and practice gaps among community oncology providers in administration protocol and adverse event (AE) management.
The goal of this project was to assess practice patterns, monitoring and management of treatment-related AEs, supportive care services, and barriers to treatment for patients with multiple myeloma.
For more information on this study contact Mary Stanley, LMSW, PMP at mstanley@accc-cancer.org.
The views and opinions expressed herein are those of the author(s)/faculty member(s) and do not reflect the official policy or position of their employer(s) or the Association of Cancer Care Centers.

2026 ACCC Innovator Award Winner St. Luke's Cancer Institute noticed a significant administrative burden being placed on providers to review medical necessity validation for complex oncology therapies. To address the resulting rise in peer-to-peer requirements, delays in care, and pre-service denials, the team designed and implemented a new Clinical Documentation Integrity Registered Nurse role.

ACCC launched its Precision Medicine Stewardship Program to highlight institutions that have successfully built the infrastructure, workflows, and leadership models needed to deliver precision medicine at scale. TriHealth Cancer and Blood Institute in Cincinnati, Ohio, offers a compelling example of what it takes to move from aspiration to execution.

Although patients with relapsed or refractory multiple myeloma now have more treatment options than ever, their journeys are often complex. As clinicians consider when to introduce newer therapies such as bispecific antibodies, they must account for prior treatments, treatment-related toxicities, and comorbidities that may impact treatment decisions.

Each year, the NCCN State Oncology Society Forum is thoughtfully organized to foster meaningful collaboration and forge common bonds to advance dignity and fair access to cancer care. In this blog, Sean T. McCarson shares key insights from stakeholders across the oncology policy landscape at this year's meeting.
